The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...

By Sneha S K and Bhanvi Satija (Reuters) -Shares of Soleno Therapeutics jumped 40% in morning trading on Thursday, after the company's drug for a rare metabolic condition became the first such ...

Soleno on Wednesday said the FDA approved its Vykat XR extended-release tablets for the treatment of hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, in people ages 4 ...

The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with Prader-Willi syndrome, Soleno Therapeutics announced. Prader-Willi syndrome is a rare ...

Laidlaw raised the firm’s price target on Soleno Therapeutics (SLNO) to $105 from $75 and keeps a Buy rating on the shares after the FDA ...

Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome, breakthrough therapy drug DCCR (diazoxide choline) gained U.S. FDA approval as Vykat XR the evening before its March 27 ...

Over 95% of babies now diagnosed with SMA are treated with Zolgensma gene therapy, per Daniel Grant, vice president for ...

The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' (SLNO.O) drug to treat a rare genetic ...

Here’s your preview for anime coming to Netflix in 2025.